The Journal of
Clinical Psychiatry

Psychopharmacology

Brainstorms December 15, 1998

Using Secondary Binding Properties to Select a Not So Selective Serotonin Reuptake Inhibitor

Stephen M. Stahl

J Clin Psychiatry 1998;59(12):642-643

Article Abstract

In an earlier BRAINSTORMS, the secondary binding characteristics of the SSRIs were examined. Here we show these graphically for all 5 agents (fluoxetine, sertraline, paroxetine, fluvoxamine, and citalopram). We also propose how such properties can create potential advantages and disadvantages for various patient profiles.

Â

Download Free PDF

Save Save

Cite

Advertisement
GAM ID: sidebar-top

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Advertisement
GAM ID: sidebar-bottom

Vol 85 • 2024 • Number 3

Read the Current Issue

Editorial

Focus on Women’s Mental Health: Twenty Years and Counting

Original Research

Esmethadone in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants

Commentary

Can Our Collective Experiences As Clinicians Improve Mental Health Care?

Original Research

Prescription Opioid Use Disorder in US Adults Reporting Prescription Opioid Use

Original Research

Symptomatic Disorders Comorbid with Borderline Personality Disorder Over Time

Original Research

Aripiprazole Lauroxil Initiation Regimens

View current Issue